PuraMed BioScience®, Inc., Launches Its Business-to-Business Migraine First Aid Kit™ to Promote Workplace Health and Wellness

May 15, 2013, 16:01 ET from PuraMed BioScience, Inc.

SCHOFIELD, Wis., May 15, 2013 /PRNewswire/ -- PuraMed BioScience®, Inc., (OTCBB: PMBS) announces the launch of its Business-to-Business Migraine First Aid Kit. The program, which is available to businesses of any size, can help migraine sufferers stay on the job and stay productive by eliminating migraine pain and associated symptoms.

"Knowing that migraines are debilitating for many people we looked at their impact on the business sector," said Charles Phillips, board member of PuraMed BioScience. "What we found was a substantial financial impact on businesses due to absenteeism and presenteeism. Insurance and healthcare costs were also significant, especially for companies that self-insure and offer employees' health benefits. We created the Business-to-Business Migraine First Aid Kit to help employees that suffer migraines stay healthy and productive throughout the workday. The kit can be ordered directly through PuraMed BioScience, and the LipiGesic M product can be distributed through a company's employee assistance program or human resources department for a fraction of the cost that a company incurs when an employee leaves work or comes to work impaired by a migraine."

The initial Business-to-Business Migraine First Aid Kit contains a box of 10, two-pack samples of LipiGesic® M, product information including a migraine cost worksheet, a "Coping with Migraine" informational booklet, a copy of the clinical trial results summary, and a reorder form. Since LipiGesic M has no reported drug interactions, an excellent safety profile, and is a non-drowsy formulation, it may be a workplace solution for many migraine sufferers.

Migraine is considered the most expensive brain disorder in the United States. According to the National Headache Foundation (NHF) migraines cost American businesses over $31 billion in direct and indirect costs. A portion of this cost can be attributed to the direct costs of healthcare including hospital admissions, doctor visits, diagnostic tests, prescription drugs, and therapies for the treatment of migraine.

The $31 billion estimate also includes the indirect costs associated with migraine, with most obvious being absenteeism and presenteeism. The NHF reports that 157 million workdays are missed annually due to migraine and associated symptoms.

"We are pleased to make this program available to employers," said Russ Mitchell, chairman and CEO of PuraMed BioScience. "LipiGesic M is highly effective in the treatment of migraine headache and associated symptoms. A clinical study conducted by three-leading US headache specialists, found that LipiGesic M reduces or eliminates migraine pain in at least 64 percent of migraine occurrences. It is safe, fast and is non-drowsy, so an employee taking LipiGesic M can be back on the job at full capacity – often in a matter of minutes."

About PuraMed BioScience, Inc.

PuraMed BioScience engages in the research, development, and marketing of non-prescription medicinal and healthcare products. In addition to LipiGesic® M, PuraMed BioScience plans to launch LipiGesic® H for tension-type headaches and LipiGesic® PM, which provides a remedy for insomnia and other sleep disorders. www.puramedbioscience.com

Forward-Looking Statements

This news release contains forward-looking statements regarding PuraMed BioScience, Inc., and its future business plans, which statements involve known and unknown risks and uncertainties that may cause actual results and future achievements of PuraMed BioScience to be materially different from those implied by these forward-looking statements. PuraMed BioScience has and undertakes no obligation to provide public updates and revisions to these forward-looking statements to reflect any changes in its expectations of future events.

Melissa Diaz,
South Street Media, Inc
Phone: (917) 937-8968
Email: info@southstreetmedia.com


SOURCE PuraMed BioScience, Inc.